Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 8Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Injections 6pembrolizumab 5toripalimab 3tislelizumab 3senaparib 3Bevacizumab 3sintilimab 2Technetium 2Specimen Handling 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Carboplatin 2Blood Specimen Collection 2zimberelimab 1tumor-cells apoptosis factor, human 1tazemetostat 1spartalizumab 1sacituzumab govitecan 1rucaparib 1osimertinib 1olaparib 1etoposide phosphate 1enzalutamide 1envafolimab 1cemiplimab 1cedazuridine 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Ultrasonography, Doppler 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumor × sintilimab × 1 year × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Fujian Haixi Pharmaceuticals Co., Ltd.

Phase 1/2 Active not recruiting
155 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡